Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis <i>-oralis</i> Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance-Reference-Cited by-同舟云学术

Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis -oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance

Published:2023-04-18 Issue:4 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Mishra Nagendra N.¹²^ORCID,Abdelhady Wessam¹,Elsayed Ahmed M.¹,Lapitan Christian¹,Proctor Richard A.³⁴,Rybak Michael J.⁵⁶^ORCID,Miro Jose M.⁷⁸,Bayer Arnold S.¹²

Affiliation:

1. Division of Infectious Diseases, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA

2. The David Geffen School of Medicine, University of California, Los Angeles, California, USA

3. Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

4. Department of Medical Microbiology & Immunology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

5. Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA

6. School of Medicine, Wayne State University, Detroit, Michigan, USA

7. Hospital Clinic, Institut d' Investigacions Biomèdiques August Pi, iSunyer, University of Barcelona, Barcelona, Spain

8. CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain

Abstract

The Streptococcus mitis -oralis subgroup of the viridans group streptococci (VGS) are the most common cause of infective endocarditis (IE) in many parts of the world. These organisms are frequently resistant in vitro to standard β-lactams (e.g., penicillin; ceftriaxone [CRO]), and have the notable capacity for rapidly developing high-level and durable daptomycin resistance (DAP-R) during exposures in vitro , ex vivo , and in vivo .

Funder

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

The Lundquist Institute for Biomedical Innovation at harbor UCLA medical center

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01472-22

Reference24 articles.

1. Holland TL, Bayer AS, Fowler VG. 2020. Endocarditis and intravascular infections, p 1068–1108. In Mandell GL, Bennett JE. (ed), Principles and practices of infectious diseases, 9th ed; Elsevier, Philadelphia, PA, USA.

2. Viridans Streptococcus Bacteremia in Children on Chemotherapy for Cancer: An Underestimated Problem

3. Viridans Streptococci Bacteremia in Children with Malignancy

4. Early In Vitro and In Vivo Development of High-Level Daptomycin Resistance Is Common in Mitis Group Streptococci after Exposure to Daptomycin

5. Clinical features and complications of viridans streptococci bloodstream infection in pediatric hemato-oncology patients;Huang WT;J Microbiol Immunol Infect,2007

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Membrane Phenotypic, Metabolic and Genotypic Adaptations of Streptococcus oralis Strains Destined to Rapidly Develop Stable, High-Level Daptomycin Resistance during Daptomycin Exposures;Antibiotics;2023-06-21